Safe Harbor

Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, expectations, intentions, projections, developments, future events, performance or products, underlying assumptions, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terms such as "believes," "beliefs," "may," "will," "should," "expects," "intends," "plans," "anticipates," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms. From time to time, we may publish or otherwise make available forward-looking statements of this nature. All such forward-looking statements, whether written or oral, and whether made by us or on our behalf, are expressly qualified by the cautionary statements described in this message including those set forth below.

Forward-looking statements are based upon management's beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. In addition, we undertake no obligation to update or revise any forward-looking statements made by us or on our behalf, whether as a result of future developments, subsequent events or circumstances, or otherwise, or to reflect the occurrence or likelihood of unanticipated events, and we disclaim any such obligation.

Forward-looking statements are only predictions that relate to future events or our future performance and are subject to known and unknown risks, uncertainties, assumptions, and other factors, many of which are beyond our control, that may cause actual results, outcomes, levels of activity, performance, developments, or achievements to be materially different from any future results, outcomes, levels of activity, performance, developments, or achievements expressed, anticipated, or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. 3D Systems' actual results could differ materially from those stated or implied in forward-looking statements. Past performance is not necessarily indicative of future results. We do not undertake any obligation to and do not intend to update any forward-looking statements whether as a result of future developments, subsequent events or circumstances or otherwise.

Further, we encourage you to review "Risk Factors" in Part 1 of our Annual Report on Form 10-K and Part II of our quarterly reports on Form 10-Q filed with the SEC as well as other information about us in our filings with the SEC. These are available at www.SEC.gov.
Key Messages

New management team executing a transformation journey

A leader in a large growth market

Full Solution capabilities with focus on application driven growth
Dr. Jeffrey Graves is President and CEO of 3D Systems and joined the company on May 26, 2020.

Prior to joining 3D Systems, from 2012 to May 2020, he served as CEO, President and Director of MTS Systems Corporation, a global supplier of test, simulation, and measurement systems. From 2005 until 2012, he served as President and CEO of C&D Technologies, Inc. He also held leadership roles with Kemet Corporation as Chief Operating Officer (2001-2003) and CEO (2003 to 2005). Previously he held a number of leadership and technical roles with GE, Rockwell Automation and Howmet Corporation.

Graves currently serves on the Board of Directors of FARO Technologies and Hexcel Corporation.

He holds a bachelor’s degree in metallurgical engineering from Purdue University. He also holds a master’s degree and PhD in metallurgical engineering from the University of Wisconsin. He has been recognized with the distinguished alumni award from both universities. He is also a master black belt in six sigma.
Purpose Statement

We are the leaders in enabling additive manufacturing solutions for applications in growing markets that demand high reliability products.
Transformation Framework

We are the leaders in enabling additive manufacturing solutions for applications in growing markets that demand high reliability products.

Focus on Key Applications within Healthcare and Industrial Markets
Experienced Management Team

Resizing + other cost reduction measures
Achieved $60M Run-Rate Cost Savings in 2020

Divest non-core assets and Invest for growth
Well positioned to leverage the sales growth as it returns and capture the market growth of additive manufacturing
Why AM? Tangible Benefits to AM Design

- Capability for Mass Customization
- Improved Lead Times
- Part / Assembly Consolidation
- Supply Chain Optimization and Flexibility
- Weight Reduction
- Precision Parts
Market Opportunity: AM Growth Estimate

**SCALE OF AM GROWTH**
Over the next 5 years, market is expected to grow on average at 24% CAGR, reaching $35B by 2024

**INDUSTRY GROWTH DRIVERS**
High focus to introduce new designs & business models that take full advantage of the manufacturing freedom

Growth is expected in system placement, material usage and printing services and replace end-use production processes

Top customers in high growth verticals - Healthcare, Automotive, Durable Goods, and Aerospace are squarely focused on AM exploration and adoption

Source: 3D Hubs

Footnote:
* The historic market size was calculated by averaging the market size reported by Wohler's associates, EY, and SmarTech.
** The forecasted market size in the media market size reported by all market analysts.
*** The worst-case and best-case scenarios were calculated starting at ±15% of the market size in 2018 and by applying 20% and 28% CAGR respectively.
Application Focus

Healthcare Solutions
- Dental Applications
- Medical Applications
  - Medical Devices
  - Simulations
  - Surgical Planning

Industrial Solutions
- Aerospace & Defense
- Transportation & Motorsports
- Investment Castings
- Jewelry
- Consumer Durables & Electronics

Focus on Key Applications within these Markets
Full Solution Provider

Services and Software
Application experts & Customer Innovation Centers
Printing process and management software tools
On Demand Manufacturing – printing services
Full service and support post-purchase

Hardware and Materials
Full range of 3D printers to address AM needs in metals, plastics and wax
Professional and production systems
100+ Materials portfolio for prototyping and production applications

Production Experience
Deep and diverse experience in production parts and applications
Proven across an install base that prints up to 500,000 production parts per day using 3D Systems solutions

Global Reach
Service Experts across 5 continents
Local to over 80% of customer base
Innovation Centers in US & Europe
Six Manufacturing locations around the globe

Capabilities to help customers evaluate, test and scale additive manufacturing into their business
Healthcare Case Study
Veterans Health Administration (VHA)

3D Systems will assist the VA with establishing additive manufacturing production capabilities for medical devices to improve treatment for U.S. Veteran patients.

VA Objectives
- COVID-19 related manufacturing
- Establish quality management system
- Develop patient-matched medical device products
- Regulatory compliance

3D Systems Solution
- Hardware / materials
- Software
- QMS & regulatory consulting
- Managed service manufacturing

Expected Outcomes
- Supply chain independence
- Improved patient care
- Retention of patients
- Reduced procedure costs
- Investment in American jobs
Customer Challenge
Machining-plus-coating traditional design and manufacturing processes lead to poor surface quality, high component variability, long process cycle times, high inventory and waste levels, and sub-optimal implant performance.

3D Systems Solution
• Factories – Two ISO13485 certified factories and validated workflows for accelerated product commercialization
• People – Application Engineers, Metals R&D Engineering Teams that can optimize Design for Manufacturing
• Hardware – DMP Flex 350 (High purity Titanium printer)
• Software – 3DXpert and customized software

Outcome
An economically viable orthopedic implant with optimized surface characteristics and mechanical properties for superior performance.
**Customer Challenge**

Traditional investment casting production methodology limits geometric design options and involves long, complex manufacturing cycle times.

**3D Systems Solution**

- Materials (resins) that provide consistent performance, accuracy and dimensional stability, with clean burnout, highly stable dimensional control and ultra-low ash content
- Software with hollow lattice filled build styles and print process parameters that provide sufficient strength for processing while being easily and efficiently removed late in the process
- Stereolithography printers that set the standard for around-the-clock, reliable high performance

**Outcome**

State-of-the-art cast metal parts with highly complex geometries to enable improved levels of performance at reduced cost
Investing for Growth

**ORGANIZATIONAL**
- Solution selling capability
- People and talent
- Customer Success Team created to focus on aftermarket efforts

**MATERIALS DEVELOPMENT**
- Polymer
  - High-temperature, lightweight materials for industrial applications

**PROGRAMS**
- Regenerative Medicine
- Roadrunner ‘High Speed Fusion’
- Product Enhancements
Regenerative Medicine

Through bioprinting, we have an opportunity to address patient needs for organs and soft tissue development using Additive Manufacturing

Industry Challenges

Demonstrate the capability to print complex thin-walled structured using biocompatible materials for applications such as tissue-on-a-chip, bioresorbable implants, grafts and solid organs

3D Systems Opportunity

To create a sustainable business to address patient outcomes through bioprinting revenue and growth

Strategy

Accelerate efforts in 2021 by leveraging the progress on United Therapeutics-funded Lung Program and our foundation in Healthcare to pursue a range of applications
“Roadrunner”
High Speed Fusion

Specific Applications

- Direct Printing: aerospace interiors and ducting, drone components, automotive under dash and under hood, and other general industrial applications
- Tooling & Fixtures: manufacturing aids, automation and robotics tooling, lift assist tooling, as well as molds and sacrificial tools
- Prototyping Parts: automotive, aerospace, medical, heavy equipment, and general industry support.

Industry Challenges

Address demanding aerospace and advanced automotive applications with size, speed and precision that exceeds current market offerings.

3D Systems Opportunity

To provide the most advanced platform of any high throughput industrial fused-filament offering in the market today

Strategy

Work with Jabil to commercialize this new 3D printing platform, leveraging 3D Systems’ materials capabilities, and accelerate adoption in the market
Q4 2020 Revenue by Market
(Unaudited)

**Healthcare Revenue Q4 QoQ**: Increase from $60.8 million in Q3 2020 to $86.6 million in Q4 2020, representing a gain of 42.4%.

**Industrial Revenue Q4 QoQ**: Increase from $75.3 million in Q3 2020 to $86.0 million in Q4 2020, representing a gain of 14.2%.

**Healthcare Revenue Q4 YoY**: Increase from $58.5 million in Q4 2019 to $86.6 million in Q4 2020, representing a gain of 48.0%.

**Industrial Revenue Q4 YoY**: Increase from $109.7 million in Q4 2019 to $86.0 million in Q4 2020, representing a decrease of (21.6%).

Quarter ended 12/31/20
$ in millions
Operating Expense Trend

Non-GAAP operating expenses decreased 15.8% in Q4 2020 compared to Q4 2019 as we saw benefits of restructuring efforts.

See appendix for a reconciliation of Non-GAAP operating expenses.
Adjusted EBITDA

*Defined as non-GAAP Operating Income plus Depreciation*

Q4 2020 improvement as a result of business growth and restructuring efforts

See appendix for a reconciliation of Non-GAAP Operating Profit and Adjusted EBITDA.
Our Transformation Journey Continues:

• Reorganization and Restructuring complete
• Exploring additional divestitures of non-core assets
• Investing for growth in core business of additive manufacturing
• Focus on operational execution
Thank You

Find out more at:

www.3dsystems.com
Appendix
## Non-GAAP Reconciliation - Operating Income (Loss) (Unaudited)

### Fourth Quarter and Full Year Non-GAAP Operating Loss

<table>
<thead>
<tr>
<th>(in millions, except per share amounts)</th>
<th>Quarter Ended December 31,</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2019</td>
</tr>
<tr>
<td>GAAP Operating income (loss)</td>
<td>$</td>
<td>0.7</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization, stock-based compensation &amp; other (1)</td>
<td>4.1</td>
<td>8.2</td>
</tr>
<tr>
<td>Legal, acquisition and divestiture related (2)</td>
<td>3.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Cost optimization plan, including severance costs (3)</td>
<td>7.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Product end of life adjustment (4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Goodwill impairment (5)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Non-GAAP Operating income (loss)</td>
<td>$</td>
<td>16.1</td>
</tr>
<tr>
<td>Depreciation (6)</td>
<td></td>
<td>6.8</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$</td>
<td>22.9</td>
</tr>
</tbody>
</table>

(1) For the quarter ended December 31, 2020, the adjustment included $0.1 in COGS and $4.0 in SG&A. For the quarter ended December 31, 2019, the adjustment included $0.1 in COGS and $8.1 in SG&A. For the twelve months ended December 31, 2020, the adjustment included $0.4 in COGS and $33.0 in SG&A. For the twelve months ended December 31, 2019, the adjustment included $0.4 in COGS and $43.4 in SG&A.

(2) For the quarter ended December 31, 2020, the adjustment included $0.1 in COGS and $3.7 in SG&A. For the quarter ended December 31, 2019, the adjustment included $0.1 in COGS and $1.4 in SG&A. For the twelve months ended December 31, 2020, the adjustment included $0.4 in COGS and $4.1 in SG&A. For the twelve months ended December 31, 2019, the adjustment included $(2.9) in Revenues, $4.1 in COGS and $5.5 in SG&A.

(3) For the quarter ended December 31, 2020, the adjustment included $1.5 in COGS and $6.1 in SG&A. For the quarter ended December 31, 2019, the adjustment included $0.1 in COGS and $0.6 in SG&A. For the twelve months ended December 31, 2020, the adjustment included $2.2 in COGS, $19.9 in SG&A and $0.1 in R&D. For the twelve months ended December 31, 2019, the adjustment included $1.8 in COGS, $5.6 in SG&A and $0.3 in R&D.

(4) For the twelve months ended December 31, 2020, the adjustment included $10.9 in COGS.

(5) For the twelve months ended December 31, 2020, the adjustment included $48.3 in Impairment of goodwill.

(6) For the quarter ended December 31, 2020, the adjustment included $3.0 in COGS, $2.5 in SG&A and $1.3 in R&D. For the quarter ended December 31, 2019, the adjustment included $3.1 in COGS, $2.5 in SG&A and $1.8 in R&D. For the twelve months ended December 31, 2020, the adjustment included $12.2 in COGS, $9.8 in SG&A and $6.4 in R&D. For the twelve months ended December 31, 2019, the adjustment included $12.6 in COGS, $10.4 in SG&A and $7.0 in R&D.

* Tables may not foot due to rounding; amounts calculated based on dollars in thousands.
## Non-GAAP Reconciliation - Operating Expense (Unaudited)

### Quarterly 2019 and 2020 Non-GAAP Operating Expenses

<table>
<thead>
<tr>
<th></th>
<th>2019 Quarter Ended</th>
<th>2019 Full Year</th>
<th>2020 Quarter Ended</th>
<th>2020 Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GAAP SG&amp;A Expenses</strong></td>
<td>$65.1</td>
<td>$254.4</td>
<td>$56.1</td>
<td>$219.9</td>
</tr>
<tr>
<td><strong>GAAP R&amp;D Expenses</strong></td>
<td>21.9</td>
<td>83.3</td>
<td>19.2</td>
<td>74.1</td>
</tr>
<tr>
<td><strong>GAAP Goodwill Impairment</strong></td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>48.3</td>
</tr>
<tr>
<td><strong>GAAP Operating Expenses</strong></td>
<td>87.0</td>
<td>337.6</td>
<td>75.4</td>
<td>342.3</td>
</tr>
</tbody>
</table>

Adjustments to R&D Expenses:
- Cost optimization plan: 0.3 → 0.1
- Total Adjustments to R&D Expenses: 21.9 → 20.5

Adjustments to SG&A Expenses:
- Amortization, stock-based compensation & other: 12.1 → 12.5
- Legal and acquisition-related: 0.7 → 4.6
- Cost optimization plan: 1.2 → 0.3
- Total Adjustments to SG&A Expenses: 14.1 → 20.4

**Non-GAAP R&D Expenses**: 21.9 → 20.5

**Non-GAAP SG&A Expenses**: 51.0 → 51.2

**Non-GAAP Operating Expenses**: $72.9 → $282.8

*Tables may not foot due to rounding; amounts calculated based on dollars in thousands.*